Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Common Mild Reactions Local irritation where the peptide was injected (minor redness or tenderness) Occasional dizziness or fatigue shortly after use Typically mild and short-lived Potential Risks Not FDA-approved for Lyme disease or any other condition Contraindicated in active cancer due to its angiogenesis-promoting properties Should be avoided during pregnancy or breastfeeding Take Precautions with Medical Guidance Since its administered via injection and isnt regulated for Lyme treatment, a professional Lyme disease expert should guide your dosing
El estatus regulatorio del BPC-157 vara segn los pases: no est aprobado como medicamento pero sigue siendo accesible como pptido de investigacin en ciertas jurisdicciones
VEGFR2 activation angiogenesis newly formed blood vessels at the injured site supply of oxygen, nutrients, immune cells
References: Barclay, R
